Novartis AG (NOVN) Given a CHF 70 Price Target by JPMorgan Chase & Co. Analysts
Novartis AG (VTX:NOVN) received a CHF 70 price objective from investment analysts at JPMorgan Chase & Co. in a research report issued on Saturday. The brokerage presently has a “neutral” rating on the stock.
Shares of Novartis AG (VTX:NOVN) traded up 0.13% during mid-day trading on Friday, reaching CHK 78.75. 5,144,966 shares of the company traded hands. The firm has a 50 day moving average of CHK 76.13 and a 200-day moving average of CHK 73.94. Novartis AG has a 52 week low of CHK 67.40 and a 52 week high of CHK 82.80.
TRADEMARK VIOLATION WARNING: “Novartis AG (NOVN) Given a CHF 70 Price Target by JPMorgan Chase & Co. Analysts” was posted by American Banking News and is owned by of American Banking News. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.americanbankingnews.com/2017/05/20/novartis-ag-novn-given-a-chf-70-price-target-by-jpmorgan-chase-co-analysts.html.
About Novartis AG
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.